Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Chapman University currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The portfolio's workload is distributed, with the 2 actions assigned to 2 distinct examiners across 2 distinct art units. This distribution indicates that the university is pursuing multiple distinct technical paths within the life sciences sector. The involvement of 2 distinct art units suggests that the pending applications cover different specialized areas of biotechnology.
The busiest examiner for the portfolio is HOPKINS, SAMANTHA LAKE, who is responsible for 1 pending office action. Because the 2 pending actions are split between 2 distinct examiners, each examiner handles a portion of the active prosecution. This arrangement requires the university to coordinate responses across different art units and examiner perspectives within the Biotechnology & Pharmaceuticals field. With 2 distinct examiners involved, the university must manage separate prosecution timelines and sets of examiner requirements. The 2 distinct art units further emphasize the technical variety in the university's current USPTO filings. This structure ensures that the portfolio's outcomes are not dependent on any single individual's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | HOPKINS, SAMANTHA LAKE | 58d overdue |
| 18222775 | NANOMEDICINES FOR TREATMENT OF DISEASE | PALENIK, JEFFREY T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | HOPKINS, SAMANTHA LAKE | 58d overdue |
| 18222775 | NANOMEDICINES FOR TREATMENT OF DISEASE | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | HOPKINS, SAMANTHA LAKE | 1641 | §103§112 | Non-Final OA | 58d overdue | Pending | Aug 18, 2023 |
| 18222775 | NANOMEDICINES FOR TREATMENT OF DISEASE | PALENIK, JEFFREY T | 1615 | §103§112 | Non-Final OA | — | Pending | Jul 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChapman University has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Samantha Lake Hopkins has the most, with 1 of Chapman University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
